Cowen

Curaleaf Announces January Investor Community Conference and Event Participation

Retrieved on: 
Friday, January 6, 2023
CSE, Needham, ATB, Cannabis, Cowen, Financial services, Curaleaf

Matt Darin, Chief Executive Officer of Curaleaf, will be participating in a fireside chat with Vivien Azer, Managing Director at Cowen, on January 10 at 9:30 – 9:55 a.m.

Key Points: 
  • Matt Darin, Chief Executive Officer of Curaleaf, will be participating in a fireside chat with Vivien Azer, Managing Director at Cowen, on January 10 at 9:30 – 9:55 a.m.
  • Curaleaf management will also be hosting investor meetings.
  • Curaleaf management will also be hosting investor meetings.
  • Curaleaf management will also be hosting investor meetings.

Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors

Retrieved on: 
Tuesday, December 6, 2022
Artificial intelligence, Drug discovery, Private, MS, Joint Planning and Development Office, Initial public offering, Safety, Biotechnology, Inflammation, Cowen Inc., Intelligence, Algorithm, Knowledge, Cowen, Oppenheimer, Machine learning, CARD, Primary sclerosing cholangitis, ASC, Fibrosis, MBA, Therapy, Institute of Liver and Biliary Sciences, Precision medicine, PIPES, Permeability, Biology, AI, GBA, Patient, Duodenitis, Pharmaceutical industry, Management, Bachelor of Pharmacy

GUILFORD, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a biotechnology company developing an artificial intelligence-powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders, today announced the appointment of Mr. Jason Fenton to its Board of Directors. Mr. Fenton is a widely recognized healthcare-focused capital markets executive who brings over 20 years of experience.

Key Points: 
  • - Company also primed to advance additional programs, including a pan-inflammasome inhibitor
    GUILFORD, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a biotechnology company developing an artificial intelligence-powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders, today announced the appointment of Mr. Jason Fenton to its Board of Directors.
  • “We are honored to have a recognized advisor join our board of directors.
  • Jason has an outstanding depth and breadth of knowledge in the biotech and life sciences sectors and an unparalleled perspective on company building and capital formation,” said Krishnan Nandabalan, Ph.D., Chairman, President, and CEO, Invea Therapeutics.
  • Invea Therapeutics, Inc., or Invea, is a clinical-stage biotechnology company developing an artificial intelligence (AI) powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders.

Curaleaf Announces December Investor Community Conference and Event Participation

Retrieved on: 
Thursday, December 1, 2022
Cannabis, Research, Cowen, CSE, Canadian Securities Exchange, OTCQX, Stifel, Grassroots, Communications satellite, Drug, Select, Curaleaf

Matt Darin, Chief Executive Officer of Curaleaf, will be participating in a fireside chat with Vivien Azer, Managing Director at Cowen, on December 6 at 1:20 1:50 p.m.

Key Points: 
  • Matt Darin, Chief Executive Officer of Curaleaf, will be participating in a fireside chat with Vivien Azer, Managing Director at Cowen, on December 6 at 1:20 1:50 p.m.
  • Curaleaf management will also be hosting investor meetings.
  • In the United States, Curaleaf currently operates in 21 states with 144 dispensaries, 29 cultivation sites, and employs nearly 6,000 team members.
  • Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF.

TILT Holdings Announces December Conference Schedule

Retrieved on: 
Thursday, December 1, 2022
NEO, EST, Union, Conference, TILT, Capital, Partnership, Shinnecock Indian Nation, Research, Cowen, Commonwealth, Shinnecock, Video game, Drug, Tech

Cowen 5 th Annual Cannabis Conference , Dec. 6-8, 2022: TILT executives will participate in one-on-one meetings during this three-day conference that incorporates innovative panel discussions hosted by members of the Cowen research team focused on various aspects of the cannabis industry.

Key Points: 
  • Cowen 5 th Annual Cannabis Conference , Dec. 6-8, 2022: TILT executives will participate in one-on-one meetings during this three-day conference that incorporates innovative panel discussions hosted by members of the Cowen research team focused on various aspects of the cannabis industry.
  • TILT helps cannabis businesses build brands.
  • Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 37 states in the U.S., as well as Canada, Israel, South America and the European Union.
  • TILT is headquartered in Phoenix, Arizona.

Edward Rubin Joins Lazard as a Managing Director in Telecommunications, Media & Entertainment Group, Financial Advisory

Retrieved on: 
Friday, November 11, 2022
Telecommunications, Networks, Internet, Finance, Asset Management, Consulting, Professional Services, Technology, Digital, Entertainment, Company, Deutsche Bank, New Zealand Media and Entertainment, UBS, Defense Finance and Accounting Service, Boston University, City, Cowen Inc., Accounting, Data infrastructure, Lazard, Cowen, LAZ, Wall Street, Media Asia Entertainment Group, LTD, Shanghai Media & Entertainment Group, Central, NYSE, Communication, Fox Entertainment Group, 2011 New Year Honours (New Zealand), Financial services, Security (finance), Telecommunication

Lazard Ltd (NYSE: LAZ) announced today that Edward Rubin has joined the firm as a Managing Director in the Telecommunications, Media & Entertainment Group within Financial Advisory.

Key Points: 
  • Lazard Ltd (NYSE: LAZ) announced today that Edward Rubin has joined the firm as a Managing Director in the Telecommunications, Media & Entertainment Group within Financial Advisory.
  • Based in New York, Mr. Rubin will advise companies in the communications infrastructure and network services sectors.
  • Weve built one of the leading Communications and Digital Infrastructure groups across Wall Street, said Garrett Baker, Global Co-Head of the Telecommunications, Media and Entertainment Group at Lazard.
  • Eddie has deep experience in Fiber and Telecommunications infrastructure and is a perfect complement to our teams active and growing practice.

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Investor, IND, Adult, Investment, Prostate cancer, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Trichloroethylene, PSMA, Nasdaq, Cluster, Webcast, Cytokine release syndrome, File, Research, Risk, MCRPC, Hand, Board, FUTURE, Half-life, Therapy, Human resources, TCE, PD-L1, News, Board of directors, Safety, FINANCIAL, CGMP, Pharmacokinetics, Cancer, Cowen, HR, Winston, Patient, Immune system, CD28, CEO, Security (finance), PD, Hematological Cancer Research Investment and Education Act, EGFR, Neurocrine Biosciences, Pharmaceutical industry, Dietary supplement, Management

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.
  • RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
    Janux has prioritized its programs to enable sufficient funding to provide key clinical data assessments for its lead programs.
  • THIRD QUARTER 2022 FINANCIAL HIGHLIGHTS:
    Cash and cash equivalents and short-term investments: As of September 30, 2022, Janux reported cash and cash equivalents and short-term investments of $338.8 million, compared to $375.0 million at December 31, 2021.
  • Net loss: For the quarter ended September 30, 2022, Janux reported a net loss of $16.7 million, compared to a net loss of $10.8 million for the comparable period in 2021.

Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer

Retrieved on: 
Monday, October 10, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, CA, Disease, Therapy, Growth, Harvey Fellows, Yale University, Cell, Patient, Biotechnology, List of life sciences, Research, NIH, Publication, PNAS, Carleton College, Company, Cowen, Industry, National, NEA, CEO, MIT, Molecular biology, Howard Hughes Medical Institute, TYK2, Massachusetts Institute of Technology, Management, Pharmaceutical industry, Nature, Biology

Sudo Biosciences (Sudo), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer.

Key Points: 
  • Sudo Biosciences (Sudo), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer.
  • Imran brings to Sudo extensive experience in corporate strategy and business development, as well as his track record of financing and building biotech companies.
  • He is exactly the type of leader Sudo needs as we advance into our next phase of growth, said Scott Byrd, CEO, Sudo Biosciences.
  • I am excited to join Sudo Biosciences and apply my experience to help patients with auto-immune diseases, said Imran Babar, Ph.D., chief business officer of Sudo Biosciences.

SWK Holdings Enhances Executive Management Team and Expands Underwriting Team

Retrieved on: 
Monday, October 3, 2022
Solution, Methodist University, Certified Fraud Examiner, BS, Certified Public Accountant, CFE, SEC, SOX, SWK, Tamas, Technology, Risk, Nasdaq, Form 10-K, Optimism, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Southern Methodist University, Certification, GAAP, Form, Wendell Pritchett, Cowen, MBA, Business administration, University, III, Growth, BCS, Initial public offering, Bachelor of Arts, Security (finance), CFO, San Francisco State University, Interim, Controller, Wachovia, IV, Deloitte, Board, Company, CPA, Wharton School of the University of Pennsylvania, Management, Finance

DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that the company has promoted Yvette Heinrichson to the role of Chief Financial Officer. Ms. Heinrichson was previously SWK's Chief Accounting Officer. SWK has also promoted John David ("J.D.") Tamas to Director of Underwriting, a newly created position at the company, and has hired Joe Moyer as an Associate.

Key Points: 
  • Mr. Staggs continued: "I would like to extend my sincerest gratitude to Charles Jacobson for his role in building SWK.
  • He has been a valued member of our leadership team since SWK's inception, and we wish him the best."
  • has an extensive credit background, and his enhanced role will allow SWK to increase underwriting throughput while maintaining strict credit standards.
  • He is a valuable member of our leadership team, and I'm pleased he is being recognized for his contributions to SWK."

Clear Sky Advisers Hires John Holl as President of North American Carbon and President of Environmental Trading

Retrieved on: 
Thursday, September 29, 2022
Sustainability, Professional Services, Environment, Finance, Carbon, ACT, Citigroup Global Markets Japan, North American Carbon Program, Assistant, LLC, Cowen, Credit Suisse First Boston, Head, Investment, CEO, Credit Suisse, Risk management, Solution, NASDAQ, Federation of Environmental Trade Associations, S.T.A.L.K.E.R.: Clear Sky, Business development, Renewable energy, Security (finance)

Clear Sky Advisers, LLC (Clear Sky), an investment manager dedicated to investing and acting sustainably, today announced that it has hired John Holl as President of North American Carbon and President of Environmental Trading.

Key Points: 
  • Clear Sky Advisers, LLC (Clear Sky), an investment manager dedicated to investing and acting sustainably, today announced that it has hired John Holl as President of North American Carbon and President of Environmental Trading.
  • Mr. Holl joins Clear Sky from ACT Commodities, where he served as Head of Business Development.
  • Shawn Singh, Founding Partner and CEO of Clear Sky Advisers, commented:
    We are thrilled to welcome John Holl to the Clear Sky team.
  • John Holl, President of North American Carbon and President of Environmental Trading, added:
    Clear Sky is revolutionizing what it means to invest and act sustainably.

Livent's Gilberto Antoniazzi to Speak at the Cowen 15th Annual Global Transportation & Sustainable Mobility Conference

Retrieved on: 
Monday, August 29, 2022
Cowen, Workforce, Livent, NYSE, Lithium, Lubricant, Conference, Industry, Online gambling

PHILADELPHIA, Aug. 29, 2022 /PRNewswire/ -- Livent Corporation (NYSE: LTHM) today announced that Gilberto Antoniazzi, chief financial officer, will speak at Cowen's 15th Annual Global Transportation & Sustainable Mobility Conference, being conducted virtually on Wednesday, September 7, 2022 at 1:40 p.m.

Key Points: 
  • PHILADELPHIA, Aug. 29, 2022 /PRNewswire/ -- Livent Corporation (NYSE: LTHM) today announced that Gilberto Antoniazzi, chief financial officer, will speak at Cowen's 15th Annual Global Transportation & Sustainable Mobility Conference, being conducted virtually on Wednesday, September 7, 2022 at 1:40 p.m.
  • Live access will be available on the Livent Investor Relations website and via the following link: https://wsw.com/webcast/cowen123/lthm/2021754 .
  • A replay of the event will also be available via the same link for a period of 90 days.
  • For nearly eight decades, Livent has partnered with its customers to safely and sustainably use lithium to power the world.